Abstract
Advanced prostate cancer is usually treated by hormonal therapy. In contrast, localized disease can be treated by various approaches including radical prostatectomy, radiation, hormonal therapy, and active surveillance. Wide variation in the treatment selection by era and country is a characteristic of prostate cancer. In this chapter, we review four large-scale observational studies across Japan conducted during different time periods. In Japan, the proportion of hormonal therapy as the treatment selection for newly diagnosed prostate cancer has decreased from 57% in 2000 to 40% in 2010, but it remains the most frequently selected treatment. During the same period, the proportion of metastatic disease for which hormonal therapy was the first treatment choice decreased from 21% to 11%, and that of patients with non-metastatic disease who selected hormonal therapy decreased from 46% to 32%. This lowered stage migration and shift toward radical treatment were the reasons for decrease in hormonal therapy in Japan. Regarding the type of hormonal therapy, the use of combined androgen blockade (CAB) increased from 59% in 2001–2003 to 74% in 2010.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReference
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7.
Akakura K, Isaka S, Fuse H, Akimoto S, Imai K, Yamanaka H, et al. Trends in patterns of care for prostatic cancer in Japan: statistics of 9 institutions for 5 years. Hinyokika kiyo Acta urologica Japonica. 1988;34:123–9.
Fujimoto H, Nakanishi H, Miki T, Kubota Y, Takahashi S, Suzuki K, et al. Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA. Int J Urol. 2011;18:876–81.
Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol. 2005;12:46–61.
Akaza H, Usami M, Hinotsu S, Ogawa O, Kagawa S, Kitamura T, et al. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol. 2004;34:329–36.
Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, et al. Current status of endocrine therapy for prostate cancer in Japan—analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol. 2007;37:775–81.
Onozawa M, Hinotsu S, Tsukamoto T, Oya M, Ogawa O, Kitamura T, et al. Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan. Jpn J Clin Oncol. 2014;44:969–81.
Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28:1117–23.
Cary KC, Punnen S, Odisho AY, Litwin MS, Saigal CS, Cooperberg MR. Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. Prostate Cancer Prostatic Dis. 2015;18:149–54.
Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR. Androgen-deprivation therapy as primary treatment for localized prostate cancer. Cancer. 2006;106:1708–14.
Cooperberg MR, Fang R, Wolf Jr JS, Hubbard H, Pendharkar S, Gupte S et al. The Current Management of Prostate Cancer in the United States: Data from the AQUA Registry. AUA Annual Meeting. 2017, Abstract no. PNFBA-07.
Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int. 2006;97:1190–3.
Chao GF, Krishna N, Aizer AA, Dalela D, Hanske J, Li H, et al. Asian Americans and prostate cancer: a nationwide population-based analysis. Urol Oncol. 2016;34:233.e7–15.
Cooperberg MR, Hinotsu S, Namiki M, Carroll PR, Akaza H. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 2016;117:102–9.
Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–42.
Wang W, Yuasa T, Tsuchiya N, Maita S, Kumazawa T, Inoue T, et al. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr Relat Cancer. 2008;15:943–52.
Akaza H. Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology. 2010;85:110–20.
The Japanese Urological Association: Clinical practice guideline for prostate cancer 2012. 1st ed. Tokyo: Kanehara Shuppan; 2012. P. 178–179.
The Japanese Urological Association: Clinical practice guideline for prostate cancer 2016. 1st ed. Osaka: Medical Review; 2016. P. 202–204.
Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol. 2009;27:4306–13.
Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2015;45:884–91.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Onozawa, M., Akaza, H. (2018). Recent Trends in Hormone Therapy for Prostate Cancer in Japan. In: Arai, Y., Ogawa, O. (eds) Hormone Therapy and Castration Resistance of Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-7013-6_2
Download citation
DOI: https://doi.org/10.1007/978-981-10-7013-6_2
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-7012-9
Online ISBN: 978-981-10-7013-6
eBook Packages: MedicineMedicine (R0)